Short answer
Allogene Therapeutics, Inc. (ALLO) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$41M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$41M
- +37.5% YoY · +18.7% QoQ
- EPS (diluted)
- −$0.19
- +38.7% YoY · +17.4% QoQ
Source: XBRL data from the Allogene Therapeutics, Inc. (ALLO) Q3 2025 10-Q on SEC EDGAR. USD.
Allogene Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue exclusively from Overland Therapeutics license; quarterly revenue and YoY change not provided
- Net loss $41.4 million for the quarter; operating or gross margin percentages not provided
- ALLO-316 strongest disclosed program: 31% confirmed ORR in high-CD70 RCC patients
- Cash and investments $277.1 million at September 30, 2025; runway expected into second half of 2027
- Workforce reduction approximately 28%; $3.3 million cash-based severance costs in Q2 2025
Risk Factors
- No new risk factors identifiable; provided section is truncated and lacks comparison with the prior 10-K
- Liquidity risk: $277.1 million in cash and investments at September 30, 2025, with no committed additional capital source
- Financial performance risk: $152.1 million nine-month net loss and $2.0 billion accumulated deficit
- Clinical-development risk: ALPHA3 FCA-arm termination required a protocol amendment, increasing costs and potentially delaying timelines
- Regulatory risk: FDA may require cema-cel approval to include a companion diagnostic tied to the ALPHA3 trial
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Allogene Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.